Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-08-22

FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)

View source ↗

Summary

FDA approved a supplemental application for BEYFORTUS (nirsevimab) from Sanofi Vaccines US Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BEYFORTUS (Nirsevimab)

Snippet

SUPPL AP for BEYFORTUS (NIRSEVIMAB)